133 related articles for article (PubMed ID: 24387309)
1. Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
Nin-Asai R; Sawada M; Matsumoto T; Saito S; Yokota K; Akiyama M
J Dermatol; 2014 Feb; 41(2):178-9. PubMed ID: 24387309
[No Abstract] [Full Text] [Related]
2. Therapy-related myelodysplastic syndrome developed by dacarbazine, nimustine hydrochloride and vincristine sulfate (DAV) therapy for patient with malignant melanoma.
Nitta Y; Ikeya T; Sakakibara A; Tomita Y
J Dermatol; 2011 Feb; 38(2):164-8. PubMed ID: 21269313
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine.
Kageshita T; Kuribayashi N; Ono T
J Dermatol; 2000 Mar; 27(3):178-80. PubMed ID: 10774145
[TBL] [Abstract][Full Text] [Related]
4. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
5. Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report.
Fukunaga T; Soejima H; Sugamura K; Kojima S; Sugiyama S; Sakamoto T; Yoshimura M; Tanoue T; Kageshita T; Ono T; Ogawa H
J Cardiol; 2006 Apr; 47(4):191-5. PubMed ID: 16637253
[TBL] [Abstract][Full Text] [Related]
6. Paralytic ileus associated with a combination of dacarbazine-nimustine hydrochloride-vincristine chemotherapy.
Takata Y; Hayashi S; Ohno T; Dekio S
J Dermatol; 1997 Oct; 24(10):682-3. PubMed ID: 9375471
[No Abstract] [Full Text] [Related]
7. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for melanoma: the resultant of conflicting vectors.
Mitchell MS
J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
[No Abstract] [Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
10. Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
Roider E; Schneider J; Flaig MJ; Ruzicka T; Kunte C; Berking C
Int J Dermatol; 2012 Sep; 51(9):1142-4. PubMed ID: 21913905
[No Abstract] [Full Text] [Related]
11. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Dufour C; Da Costa L; Auger N; Jullien M; Bhangoo R; Grill J
J Pediatr Hematol Oncol; 2008 Nov; 30(11):857-9. PubMed ID: 18989164
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of malignant melanoma].
Ishihara K; Yamazaki N; Asano K
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
Gundersen S
Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
[No Abstract] [Full Text] [Related]
16. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
17. [Current chemo- and hormone therapy in disseminated malignant melanoma of the skin].
Akimov MA; Gershanovich ML
Vopr Onkol; 1999; 45(4):341-9. PubMed ID: 10532089
[No Abstract] [Full Text] [Related]
18. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
19. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
20. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
Vorobiof DA; Sarli R; Falkson G
Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
